News from NORD

Letter to Congress: NORD and Others Oppose “Right to Try”


 

NORD and 40 other patient organizations and professional societies have sent a letter to the leadership of the US House of Representatives explaining why they oppose “Right to Try” legislation currently being considered by Congress. Signers of the letter include the American Society of Clinical Oncology, Leukemia & Lymphoma Society, American Lung Association, and National Health Council. The organizations say they support patients being given access to unapproved therapies but believe the bills under consideration will not increase patient access.

Recommended Reading

Join 7,000 Miles Campaign to Support Programs for Rare Disease Patients
Clinician Reviews
January 12 Is Deadline for Rare Impact Awards Nominations
Clinician Reviews
NORD Awards Five Research Grants
Clinician Reviews
Visit NORD’s Website to Learn About Current or Future Research Funding Opportunities
Clinician Reviews
NORD Launches Year-Long 35th Anniversary Observance
Clinician Reviews
NORD Provides Update on Tax Cuts and Jobs Act
Clinician Reviews
FDA Issues Guidance for More Efficient Approach to Drug Development for Rare Pediatric Diseases
Clinician Reviews
NIH Undiagnosed Diseases Network to Offer Grand Rounds Webinar Series
Clinician Reviews
NORD to Moderate Panel at NIH Rare Disease Day Event
Clinician Reviews
Rare Disease Day Events Planned for Campuses, Hospitals, and State Legislatures
Clinician Reviews